{"id":"W2316810850","doi":"10.1158/1535-7163.targ-09-a105","title":"Abstract A105: Phase 2 trials of linifanib (ABT-869) in advanced hepatocellular, renal cell and non-small cell lung cancer: Associations of response by CT or DCE-MRI with patient outcome","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Hazard ratio; Oncology; Internal medicine; Hepatocellular carcinoma; Progression-free survival; Cancer; Clinical trial; Lung cancer; Phases of clinical research; Sorafenib; Interim analysis; Nuclear medicine; Urology; Overall survival; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00370639,0.0006178365,0.000796569,0.0003845048,0.0002336013,0.0006465538,0.0004349721,0.0005306721,0.003324258],"category_scores_gemma":[0.002071636,0.0001934491,0.0009103791,0.0003510975,0.0003944596,0.0004601447,0.000236179,0.001075913,0.0004961376],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005865152,"about_ca_system_score_gemma":0.001031224,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003770526,"about_ca_topic_score_gemma":0.001049419,"domain_scores_codex":[0.9983703,0.001164793,0.0001086635,0.0001351779,0.0001300891,0.00009100681],"domain_scores_gemma":[0.9978756,0.0006958929,0.0006185375,0.0001434324,0.0001803703,0.0004862136],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8205362,0.01512061,0.06200076,0.0007875937,0.003199578,0.0002565336,0.0001334827,0.0014561,0.02753683,0.0001778055,0.003649297,0.06514531],"study_design_scores_gemma":[0.2796108,0.5119041,0.1858601,0.00009455857,0.002755341,0.0005431671,0.00007668519,0.003433482,0.01014371,0.0003035079,0.005235741,0.0000387101],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920915,0.001957089,0.0008403033,0.0002391511,0.00005016515,0.001657821,0.001798939,0.00007486041,0.001290154],"genre_scores_gemma":[0.9893079,0.0005176493,0.002094032,0.0004194143,0.0001507424,0.001793431,0.003836127,0.00001842202,0.001862304],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00370639,"threshold_uncertainty_score":0.01960152,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03472244194285886,"score_gpt":0.3741749619326415,"score_spread":0.3394525199897827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}